胃癌多药耐药逆转短肽GMBP42的活性鉴定

目的：鉴定短肽GMBP42与胃癌多药耐药细胞（SGC7901/VCR和SGC7901/ADR）的结合特异性及其多药耐药逆转活性。方法：体外培养胃癌亲本细胞SGC7901及多药耐药细胞（SGC7901/VCR和SGC7901/ADR）。免疫细胞化学染色技术鉴定短肽GMBP42与多药耐药细胞的结合特异性。体外药物敏感实验测定短肽GMBP42对多药耐药细胞化疗药物敏感性的影响。结果：免疫细胞化学染色结果显示：短肽GMBP42能够与胃癌多药耐药细胞（SGC7901/VCR和SGC7901/ADR）结合,亚细胞定位于核周胞浆及胞膜,而与亲本细胞无明显结合。体外药物敏感试验结果显示：与对照组相比,短肽GMBP42处理组胃癌多药耐药细胞（SGC7901/VCR和SGC7901/ADR）对化疗药物的IC50值及细胞存活率均降低（P〈0.05）。结论：短肽GMBP42能特异结合于多种胃癌多药耐药细胞,短肽GMBP42可提高胃癌多药耐药细胞对阿霉素的敏感性,部分逆转多药耐药细胞对阿霉素的耐药表型。

Identify activity of new multidrug-resistant reversal short peptide GMBP42 in gastric cancer

Objective：To identify the binding effect of short peptide GMBP42 to the multidrug-resistant gastric cancer cells（SGC7901/VCR and SGC7901/ADR） and its function of reversing multidrug-resistant phenotype of these cells.Methods：We exploited gastric cancer parental cells SGC7901 and multidrug-resistant cells（SGC7901/VCR and SGC7901/ADR） in our experiment.The ability of short peptide GMBP42 specifically binding to multidr-ugresistant cells was detected by immunocytochemical staining.In vitro drug sensitivity assay was applied to evaluate the change of drug resistance of multidrug-resistant cells with or without the short peptide GMBP42.Results：The results of immunocytochemial staining showed that the peptide GMBP42 could specifically bind to SGC7901/VCR and SGC7901/ADR cells with its location at the surface and in the perinuclear cytoplasm of cells compared to the parental cells SGC7901.In vitro drug sensitivity assay showed that peptide GMBP42 could reduce the survival rate of SGC7901/VCR and SGC7901/ADR cells and decrease the IC50 of adriamycin compared with control groups（P0.05）.Conclusion：The short peptide GMBP42 could specifically bind to multidrug-resistant gastric cancer cells but also enhance the sensitivity and partly reverse the resistance phenotype of gastric cancer multidrug-resistant cells to adriamycin.